Can nebulised heparin reduce acute lung injury in patients with SARS‑CoV‑2 requiring advanced respiratory support in Ireland: the CHARTER‑Ireland phase Ib/IIa, randomised, parallel-group, open-label study

Can nebulised heparin reduce acute lung injury in patients with SARS‑CoV‑2 requiring advanced respiratory support in Ireland: the CHARTER‑Ireland phase Ib/IIa, randomised, parallel-group, open-label study

Abstract Background Nebulised unfractionated heparin may attenuate COVID-19 ARDS by reducing pulmonary microvascular thrombosis, blocking SARS-CoV-2 entry into cells, and decreasing lung inflammation. COVID-19 patients with a raised d-dimer have areas of pulmonary hypoperfusion on CT perfusion scans...

Full description

Saved in:
Bibliographic Details
Main Authors: David Cosgrave, Bairbre McNicholas, Ciara Hanley, John Robert Sheehan, Padraig Calpin, Maeve Kernan, Darragh Murphy, Alberto Alvarez‑Iglesias, John Ferguson, Camilla Giacomini, Christine Greene, Catriona Cody, Shane McGeary, Marion Murphy, Marianne Fitzgerald, Gerard Curley, Barry Dixon, Roger J. Smith, Claire Masterson, Daniel O’Toole, Frank van Haren, John G. Laffey
Format: Article
Language:English
Published: SpringerOpen 2025-02-01
Series:Intensive Care Medicine Experimental
Subjects:
Heparin
Nebulised
Aerosol delivery
COVID-19
Acute respiratory distress syndrome
Safety study
Online Access:https://doi.org/10.1186/s40635-025-00727-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40635-025-00727-x

Similar Items